
    
      This is a randomized double-blind, placebo-controlled, single centre Phase I study.

      Thirty-six (36) subjects are planned to be randomised at

      1 site across the 2 parts of the study as follows:

        -  Part A (Single Ascending Dose (SAD) in healthy subjects)

        -  Part B (Multiple Ascending Doses (MAD) in healthy subjects)
    
  